Ayurvedic treatment of COVID-19: A case report

Girija, P.L.T.; Sivan, Nithya

doi:10.1016/j.jaim.2020.06.001

Cited by 83 publications

(73 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A preliminary Ayurvedic clinical profile of COVID-19 has already been published characterising the disease as a variant of vātakaphasannipātajvara with pittānubandha [ 14 ]. A case report has described the outcomes of Ayurvedic intervention in a COVID-19 patient with severe breathing difficulty who recovered with only supportive Ayurvedic care [ 15 ]. A pragmatic Ayurvedic treatment protocol for management of COVID-19 has also been proposed in a research publication [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Outcomes of Ayurvedic care in a COVID-19 patient with hypoxia – A case report

Joshi¹,

Manohar²

2022

Journal of Ayurveda and Integrative Medicine

View full text Add to dashboard Cite

This paper reports for the first time, the outcomes of Ayurvedic intervention in a COVID-19 patient with severe hypoxia requiring supportive oxygen therapy. Patient developed fever, severe cough, loss of smell, loss of taste, nasal block, anorexia, headache, body ache, chills, and fatigue and was hospitalised when she developed severe breathing difficulty. Later, she tested positive for COVID-19 by RT PCR. The patient sought Ayurvedic treatment voluntarily when her SPO2 remained at 80% even after being given oxygen support. The patient was administered Ayurvedic medicines while undergoing oxygen therapy at the hospital. The patient refused to take Fabiflu recommended by the treating physician and discontinued other allopathic drugs except for Vitamin C. The patient showed clinical improvement within a day of administration of Ayurvedic medicines and was able to talk, eat, and sit on the bed without breathing difficulty and her SPO2 became stable between 95 and 98%. In the next two days, she was asymptomatic without oxygen support and was discharged from the hospital in the following week. Since obesity and high plasma CRP indicated high risk for progression to severe disease, the favourable outcomes with Ayurvedic treatment in this patient is significant and warrants further studies. Ayurveda care may be considered as first-line cost-effective alternative for COVID-19 patients presenting with symptomatic hypoxia in an integrative setup.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcomes of Ayurvedic care in a COVID-19 patient with hypoxia – A case report

Joshi¹,

Manohar²

2022

Journal of Ayurveda and Integrative Medicine

View full text Add to dashboard Cite

show abstract

“…In this context, traditional Indian herbs of prophylactic relevance could serve as effective strategy to counter viruses like SARS-CoV-2 and have potential to prevent disease deterioration into a critical state [ 8 , 77 ]. Recently in silico and experimental observations affirmed therapeutic potency of Qingfei Paidu Decoction in treating COVID-19 patients in China [ 78 ].…”

Section: Discussionmentioning

confidence: 99%

‘BhAVI-23’-A spice-herb based dietary infusion possessing in-vitro anti-viral potential

Saxena

Kumar

Hajare

et al. 2021

Journal of Ayurveda and Integrative Medicine

View full text Add to dashboard Cite

“…Although the efficacy of phytoconstituents and herbal plants in reducing the SARS-CoV-2 severity is under investigation, a systematic meta-analysis of Chinese Herbal Medicines suggests that herbal medicines may improve clinical outcomes when used in conjunction with conventional medical care (Fan et al, 2020). Moreover, a single case study reported a combination of herbal medicines comprising of several herbal plants enabled the patient to recover from COVID-19 (Girija and Sivan, 2020). Herbal medicines may be useful for the prevention, treatment of mildly symptomatic, severe, and recovering COVID-19 patients (Lee et al, 2020).…”

Section: Molecular Docking Against Orf8mentioning

confidence: 99%

Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection

Goyal¹,

Majeed²,

Tonk³

et al. 2020

Reviews in Cardiovascular Medicine

View full text Add to dashboard Cite

Angiotensin-converting enzyme 2 (ACE2), the host cellbinding site for SAR-CoV-2, poses twofold drug development problems. First, the role of ACE2 itself is still a matter of investigation, and no specific drugs are available targeting ACE2. Second, as a consequence of SARS-CoV-2 interaction with ACE2, there is an impairment of the renin-angiotensin system (RAS) involved in the functioning of vital organs like the heart, kidney, brain, and lungs. In developing antiviral drugs for COVID-19, ACE2, RNAdependent RNA polymerase (RdRp), and the specific enzymes involved in the viral and cellular gene expression have been the primary targets. SARS-CoV-2 being a new virus with unusually high mortality, there has been a need to get medicines in an emergency, and the drug repurposing has been a primary strategy. Considering extensive mortality and morbidity throughout the world, we have made a maiden attempt to discover the drugs interacting with RAS and identify the lead compounds from herbal plants using molecular docking. Both host ACE2 and viral RNA-dependent RNA polymerase (RdRp) and ORF8 appear to be the primary targets for the treatment of COVID-19. While the drug repurposing of currently approved drugs seems to be one strategy for the treatment of COVID-19, purposing phytochemicals may be another essential strategy for discovering lead compounds. Using in silico molecular docking, we have identified a few phytochemicals that may provide insights into designing herbal and synthetic therapeutics to treat COVID-19.

show abstract

Ayurvedic treatment of COVID-19: A case report

Cited by 83 publications

References 2 publications

Outcomes of Ayurvedic care in a COVID-19 patient with hypoxia – A case report

Outcomes of Ayurvedic care in a COVID-19 patient with hypoxia – A case report

‘BhAVI-23’-A spice-herb based dietary infusion possessing in-vitro anti-viral potential

Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection

Contact Info

Product

Resources

About